Virinchi Ltd. · NSE:VIRINCHI

Virinchi — Q3 FY2022 Earnings Presentation

49 slides from Virinchi's earnings presentation, Jan 28, 2022

  1. Slide 1: Regulation 30 filing letter to BSE

    Date: 28th January, 2022 To, The Manager, Dept. of Corporate Services, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 Dear Sir/Madam, Sub: Investors Presentation-Reg. Ref: Script Code# 532372 With reference to the Regulation 30 of the SEBI( LODR) Regulations, 2015, please find

  2. Slide 2: Investor Presentation

    INVESTOR PRESENTATION

  3. Slide 3: Safe Harbor

    Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Virinchi Ltd. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and

  4. Slide 4: Rise of a Multicorn

    Rise of a Multicorn UPI Credit Healthcare -vCard Virinchi Chain of Hospitals Cards Issued – 20,000+ Revenue - Rs. 1,610 Mn Credit Issued - Rs. 200 Mn/ EBITDA - Rs. 498 Mn month Healthcare Aggregator Credit Bazaar Business IDC & IT SaaS Revenue - Rs. 550 Mn Revenue - Rs. 1,350 Mn EBITDA - Rs. 113 Mn

  5. Slide 5: 4 Revenue Streams

    4 Revenue Streams 1. SaaS 2. IDC & IT Services Loan management solution for NBFC’s in US Datacenters at California and Atlanta IT Services (Security and Cloud ) 3. Credit Bazaar Providing Line of Credit for UPI transactions in India via mobile app, vCard 4. Healthcare Chain of 3 Hospitals with 700 b

  6. Slide 6: 1st Revenue Stream - SaaS Business

    1st Revenue Stream - SaaS Business

  7. Slide 7: 1st Revenue Stream - SaaS Business

    1st Revenue Stream - SaaS Business SaaS-based end-to-end loan management system for global clients Annuity Income business Adaptive pricing [Per transaction/ per license/ per store] SaaS Used by 18 NBFC’s in US across 20,000+ Point of Sale locations across 45 states in the US A mission-critical solu

  8. Slide 8: SaaS Product Variants

    »® SaaS Product Variants virinchi Limited QFund™ provides a Ji MSenmereelits Instalment. Title / Buy Now, Pay Line of Credit complete solution for Salary Loan Auto Equity Later (BNPL) (Secured / managing the Payday Unsecured) loan t ions loans that are d bursed to borrowers in return for checks draw

  9. Slide 9: SaaS - Works as an Omni-channel

    SaaS - Works as an Omni-channel Loan Pay Anywhere Website Anywhere Mobile SaaS Store

  10. Slide 10: Cross Sectional View of SaaS

    A) e Cross Sectional View of SaaS virinchi Limited Integrations “Bek crveriry veritec ERR Cbefax Ea ieee. Qmoxmind

  11. Slide 11: SaaS – 7 Years' KPIs

    SaaS – 7 Years’ KPIs Year wise Loans (# in Million) Year wise Loans ( $ Billion) 29,000,000 $14,700,000,000 Total Total Loan Number of Amount Loans Sanctioned Sanctioned Year wise Payments (# in Million) Year wise Payments ( $ Billion) 62,900,000 $14,000,000,000 Total Total Amount Number of Processe

  12. Slide 12: SaaS – 7 Years' KPIs

    SaaS – 7 Years’ KPIs Year wise Disbursements (# in Million) Year wise Customer (Borrower) Acquisition (# in 23,100,000 Million) 12,300,000 Total Number 1.6 Total of Number of Disbursements 1.4 Unique Borrower 1.2 Accounts 1.0 0.8 0.6 Year wise Disbursements ($ Billion) 0.4 $9,920,000,000 0.2 Total D

  13. Slide 13: SaaS Financials [FY 2020-21]

    SaaS Financials [FY 2020-21] Rs. Rs. PEER COMPARISON

  14. Slide 14: SaaS Financials [Q3 & 9M – FY 21 & 22]

    SaaS Financials [ Q3 & 9M – FY 21 & 22] Segmental Revenue Segmental EBIT Comparative analysis [ Q3– FY 21 & 22] Comparative analysis [ Q3– FY 21 & 22] 34.48 29.58 3.76 3.28 FY21 FY22 FY21 FY22 Comparative analysis [ 9M– FY 21 & 22] Comparative analysis [ 9M– FY 21 & 22] 102.32 12.13 89.79 9.68 FY21

  15. Slide 15: 2nd Revenue Stream – Data Centres & IT Services

    2nd Revenue Stream – Data Centres & IT Services Speed, Scalability and Agility

  16. Slide 16: IDC & IT Services - Journey so far

    IDC & IT Services - Journey so far Boutique Web hosting services SOC-2 Certified data centers for with data centers in California & application hosting Atlanta Manages turnkey projects for US clients IDC A 75 people US team together with a 150 people across industries with multiple engagements in He

  17. Slide 17: Data Centre - Robustness

    Data Centre - Robustness Industry best uptime Multi-level data Multi-level redundancy SLA of 99.995% & backups, for power, network, industry-lowest design 24/7 monitoring & servers & storage. PUE. automated alerts. Hyperscale data center, Choice of Hypervisor Data replication via Implementation spre

  18. Slide 18: IDC & IT Services Financials [Q3 & 9M – FY 21 & 22]

    IDC & IT Services Financials [Q3 & 9M – FY 21 & 22] Segmental Revenue Segmental EBIT Comparative analysis [ Q3– FY 21 & 22] Comparative analysis [ Q3– FY 21 & 22] 5.38 15.5 12.87 0.65 FY21 FY22 FY21 FY22 Comparative analysis [ 9M– FY 21 & 22] Comparative analysis [ 9M– FY 21 & 22] 10.26 42.4 40.74 2

  19. Slide 19: 3rd Revenue Stream - Credit Bazaar

    3rd Revenue Stream - CREDIT BAZAAR Credit Service Aggregator Business TM vCard Line of Credit for UPI Payments via Mobile App

  20. Slide 20: vCard USP's

    vCard USP’s “Acceptance network-Independent” credit platform using UPI rails for transaction closure. Credit decisioning based on Machine learning based multi-parametric model End-to-end digitized loan life cycle across origination, on boarding, disbursals, collections, servicing and regulatory comp

  21. Slide 21: UPI-Based Credit Card

    UPI-Based Credit Card virinchi Limited Acceptance network dependence No No Yes Yes Yes 2 | ML based Credit Rating Yes Yes Yes Yes Yes 3 | Equity Loss due to Loan defaults No Yes Yes Yes Yes 4 | Income from customer Onboarding Yes No No No No 5 | Cash Back/ Discounts impacting P&L No Yes Yes Yes Yes

  22. Slide 22: KPIs of vCard as of Jan 15th 2022

    KPIs of vCard as of Jan 15th 2022

  23. Slide 23: Industry Opportunity and Growth Prospect

    Industry Opportunity and Growth Prospect Existing 5.89 Cr Credit Card ~80 Cr+ underpenetrated Potential for INR 10 Lakh Cr holders are <5% of the potential customers LOC market *Internal estimate - basis data procured from *Source: Statista (Published on July 09 2021) Statisa on 9 July 2021 *Interna

  24. Slide 24: 4th Revenue Stream- Healthcare Business

    4th Revenue Stream- Healthcare Business

  25. Slide 25: Healthcare Journey (2016 – Till Date)

    Healthcare Journey (2016 – Till Date)

  26. Slide 26: Healthcare Metrics

    Healthcare Metrics Cardiology Orthopedics Nephrology Neurology Emergency Medicine Key Associated Treated Key Associated Treated Key Associated Treated Key Associated Treated Key Associated Treated Faculties Doctors Patients Faculties Doctors Patients Faculties Doctors Patients Faculties Doctors Pati

  27. Slide 27: Right to Science

    _ . @ ie Right to Science virincht Ll RIGHT TO SCIENCE IN THERAPY The future is all about stem cell-based therapies organ regeneration, adoptive immune therapies, check point inhibition therapies, reconstruction surgeries, gene editing, ully-quided EQUIPMENT BASED ON surgeries, implants and transpla

  28. Slide 28: Patient Experience Patient Data

    Patient Experience Patient Data

  29. Slide 29: Digitalized Healthcare

    PT Digitalized Healthcare — “MOBILE” VIDEO CONSULTATION Virinchi provides video consultations with doctors via smartphones. MEDICAL EVENT BOOK KEEPING Virinchi’s mobile app enables each patient to have complete medical history of every test and hospitalization record on the cloud and on the mobile a

  30. Slide 30: V23 - Healthcare Aggregator

    Virinchi Tertiary Care Hospital (Metro 1) V23 - Healthcare Aggregator Labs & Diagnostics Doctors ( to be launched soon) Centers Small Town/District Clinics Virinchi Tertiary Care Nursing Homes Hospital (Metro 5) Primary Healthcare Physical Medical Virinchi Tertiary Care V23 Pharmacy Logistics Store

  31. Slide 31: Healthcare Financials [FY 2020-21] Peer Comparison

    Healthcare Financials [FY 2020-21] ₹ 160.85 Cr Revenue Peer Comparison

  32. Slide 32: Healthcare Financials [Q3 & 9M – FY 21 & 22]

    Healthcare Financials [Q3 & 9M – FY 21 & 22] Segmental Revenue Segmental EBIT Comparative analysis [ Q3– FY 21 & 22] Comparative analysis [ Q3– FY 21 & 22] 35.44 35.85 3.13 0.42 FY21 FY22 FY21 FY22 Comparative analysis [ 9M– FY 21 & 22] Comparative analysis [ 9M– FY 21 & 22] 21.23 144.51 116.27 6.84

  33. Slide 33: Management Team

    2® ® virinchi Limited Management Team

  34. Slide 34: Chairman Emeritus's Strategic Overview

    Chairman Emeritus’s Strategic Overview Alumnus of IIT Madras, First Generation Serial Entrepreneur with interests in ICT, Healthcare, Education, Life Sciences and Entertainment Commenting on the Strategy Virinchi adopts “ Bundling and Unbundling” strategy to enhance enterprise value. We see the busi

  35. Slide 35: Management Team

    Management Team SATYANARAYANA VEDULA MADDALA VEERA SATYAJEET PRASAD ABHISHEK GOEL SUYOG DESARDA Vice Chairman & SIRINIVASA RAO Chief Executive Officer VP Business Development VP Strategy & Business Development Executive Director Group CFO & B.Tech (IIT-KHP), MBA- (IIM-L) B.Tech (IIT-D), MBA (IIM-C)

  36. Slide 36: Finance & Compliance Team

    Finance & Compliance Team Deepthi Gadde Vineetha Reddy Jekkileti Vaishali Sabita D. Ravindranath Tagore Kolli CFO (Virinchi Capital) Sr. Manager (Finance & Strategy) Sr. Manager (Finance & Strategy) Company Secretary FCA CA CA CS ▪ 17+ years of experience in ▪ 3 years of experience in handling • 3 y

  37. Slide 37: Technology Team

    Technology Team Aravind Hiremath Amar Sivaji Pendyala Rajesh Putta President IT COO CTO B.E (CSE) MS (IT) MS (IT) ▪ 22 years experience in Design & ▪ 18+ years in Development & ▪ 15+ years experience in IT. Development including Enterprise Delivery of Enterprise IT ▪ Worked at ADP as Chief Architect

  38. Slide 38: Healthcare Team

    Healthcare Team Dr. Srinivas Samavedam Dr. K.S. Nayak Dr. Sumeet Sinha Dr. Avinash Dal Dr. Sree Durga Patchava Director Advisor to the Board Sr. Interventional Cardiologist Cardiothoracic and Vascular Surgeon Fertility Specialist & Gynaecologist MD, FRCP, MRCP, MHA MD, DNB(Nephrology), FISN, MBBS, M

  39. Slide 39: Financials

    Financials Causing Systems Perform Business

  40. Slide 40: Segmental Performance (Rs. Cr.)

    Segmental Performance (Rs. Cr.) Segmental Revenue Segmental EBIT Segmental EBIT Margin 24.20% 23.09% 18.24% 18.07% 16.86% 11.88% 162.09 10.79% 10.78% 160.85 19.25 144.51 11.54 63.27 6.15% 54.77 29.06 24.37 42.4 151.22 34.91 3.37 135.44 10.26 89.79 14.62 9.68 FY20 FY21 9MFY22 FY20 FY21 9MFY22 FY20 FY

  41. Slide 41: Consolidated Income Statement [Q3 & 9M FY 2021 – 2022]

    Consolidated Income Statement [Q3 & 9M FY 2021 – 2022] Particulars (Rs. Cr.) Q3FY22 Q3FY21 Change 9MFY22 9MFY21 Change FY21 FY20 Consolidated Revenue 83.55 93.74 -10.87% 285.40 272.77 4.63% 365.19 383.16 Material Cost 5.09 7.09 25.84 19.07 23.09 23.78 Employee Expenses 25.14 28.25 77.63 84.36 109.90

  42. Slide 42: Consolidated Balance Sheet

    Consolidated Balance Sheet Sources of Funds Application of Funds Rs. Cr. Mar-21 Mar-20 Rs. Cr. Mar-21 Mar-20 Equity Fixed Assets Tangible Assets (Including CWIP) 330.59 309.94 Equity Share Capital 36.99 32.72 Intangible Assets 83.01 89.46 Other Equity 338.11 341.45 Lease hold Assets (ROU) 91.88 - NE

  43. Slide 43: Historical Performance

    Historical Performance Particulars (Rs. Cr.) FY16 FY17 FY18 FY19 FY20 FY 21 CAGR Consolidated Revenue 220.5 288.6 342.5 411.1 383.2 365.19 10.6% Material Cost - 6 13 24 24 23 Employee Expenses 93 123 131 128 123 110 Administration Expenses 94 94 102 134 124 125 EBITDA 33.3 65.8 96.9 124.2 112.3 106.

  44. Slide 44: Historical Performance (Rs. Cr.)

    Historical Performance (Rs. Cr.) EBITDA 5Y CAGR : 26.2% 124.18 411.11 112.28 106.7 96.92 383.16 65.8 5Y CAGR : 10.6% 365.19 341.42 FY17 FY18 FY19 FY20 FY 21 5Y CAGR ~11% 286.68 PAT 5Y CAGR : -30.3% 58.92 46.46 218.34 33.02 23.6 2.67 138.77 FY17 FY18 FY19 FY20 FY21 112.97 18.9 78.68 EPS 68.05 5Y CAGR

  45. Slide 45: Performance Metrics

    Performance Metrics Average Return on Capital Employed Average Return on Equity Total Debt : Equity 20.6% 20.0% 0.90 14.0% 14.3% 14.3% 14.0% 0.77 16.5% 14.2% 13.8% 0.58 11.4% 0.51 11.2% 0.45 0.43 0.7% FY16 FY17 FY18 FY19 FY20 FY21 FY16 FY17 FY18 FY19 FY20 FY 21 FY16 FY17 FY18 FY19 FY20 FY21

  46. Slide 46: Stock Performance & Movement (2001 – 25th Jan 2022)

    Stock Performance & Movement (2001 – 25th Jan 2022) “There are decades where nothing happens; and there are weeks where decades happen” - Vladimir Ilyich Lenin.

  47. Slide 47: Bundling to Achieve Scale and Size

    Bundling to Achieve Scale and Size SaaS IDC & IT Credit Bazaar Healthcare Increase business Increase Marketing Add IT Teams Acquire hospitals from existing Spend to acquire customers and increase beds. Customers Acquire new Add Server Farms Start Brownfield customers Add Lending Projects Partners (B

  48. Slide 48: Way Forward: Value creation by Vanilla & Tequila Strategy

    Way Forward: Value creation by Vanilla & Tequila Strategy 2024-25 Vanilla Growth New product / Tequila Shot Vanilla Model is an organic Service Launch Mergers & Demergers growth model of enhancing top line by acquiring more clients, expanding to new geographies and launching new products by 2023-24

  49. Slide 49: Thank You

    THANK YOU For further information, Please contact Virinchi Ltd. CIN - L72200TG1990PLC011104 Mr. Ravindranath Tagore [email protected] www.virinchi.com

Virinchi — Q3 FY2022 Earnings Presentation on 6ix